Cara Therapeutics to Participate in Webcast on Pain Targeting Mechanisms
October 03 2016 - 8:00AM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that Dr. Derek
Chalmers, President and Chief Executive Officer, will participate
in a webcast featuring innovations in pain management therapies.
The webcast is part of a series from Biopharma Dealmakers, a
quarterly supplement in Nature Biotechnology and Nature Reviews
Drug Discovery.
Four companies that are working to address unmet
needs in pain management will present their developments, which
include analgesics with novel mechanisms of action, medical
devices, and opioids with reduced potential for abuse and physical
dependence. The webcast will also include a roundtable discussion
and a question and answer session with Dr. Chalmers and the other
speakers.
Details for the webcast are as follows:
Date: Thursday, October
6, 2016Time: 11:00 a.m.
ETModerator: Raveena Bhambra, Editor of
BioPharma DealmakersParticipants:
- Dr. Derek Chalmers, President and CEO of Cara Therapeutics
- Dr. Jeffrey Herz, President and CEO of Algomedix, Inc.
- Dr. Jessica Preciado, Director of Product Development and
Principal Scientist of Myoscience
- Dr. Steve Doberstein, Senior Vice President and Chief
Scientific Officer of Nektar Therapeutics
For more information, and to register for this free webcast,
visit:
http://www.workcast.com/register?cpak=5922214840089056&referrer=SPONSOR_CaraTherapeutics.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biotechnology company focused on developing and commercializing new
chemical entities designed to alleviate pain and pruritus by
selectively targeting peripheral kappa opioid receptors. Cara is
developing a novel and proprietary class of product candidates that
target the body's peripheral nervous system and have demonstrated
initial efficacy in patients with moderate-to-severe pain without
inducing many of the undesirable side effects typically associated
with currently available pain therapeutics.
INVESTOR CONTACT:
Jesse Baumgartner
Stern Investor Relations, Inc.
212-362-1200
Jesse@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2024 to May 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From May 2023 to May 2024